Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective

R.E.Mansel

首页> 外文期刊>European Journal of Cancer Supplements >Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective

【24h】

Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性辅助治疗的成本效益：英国国家卫生服务部门的观点

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第3期|共2页
作者
R.E.Mansel;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective [J] . R.E.Mansel European Journal of Cancer Supplements . 2004,第3期

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性辅助治疗的成本效益：英国国家卫生服务部门的观点
2. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen [J] . Locker GY, Mansel R, Cella D, Breast cancer research and treatment. . 2007,第2期

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性患者的主要辅助治疗的成本-效果分析：美国医疗保健系统的观点。对ATAC（'Arimidex'，他莫昔芬，5年完成的治疗分析
3. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial [J] . Gershon Y. Locker, Robert Mansel, David Cella, Breast Cancer Research and Treatment . 2007,第2期

机译：阿那曲唑与他莫昔芬作为绝经后早期乳腺癌女性患者的主要辅助治疗的成本-效果分析：美国医疗保健系统的观点。对ATAC（“ Arimidex”，他莫昔芬单独治疗或联合治疗）的5年完成治疗分析
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. Dietary associations with biomarkers of breast cancer risk in women on adjuvant tamoxifen therapy. [D] . Strom, Meghan Brianna. 2016

机译：辅助性他莫昔芬治疗妇女饮食中与乳腺癌风险生物标志物的关联。
6. Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial [O] . The ATAC Trialists Group 2001

机译：绝经后妇女在早期乳腺癌的辅助内分泌治疗中单独使用或联合使用阿那曲唑和他莫昔芬的药代动力学： Arimidex™和他莫昔芬单独或联合使用（ATAC）试验的子协议
7. CN4 COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE [O] . Á Benedict 2004

机译：纳曲唑对他莫昔芬作为早期治疗绝经后女性早期乳腺癌（EBC）的辅助疗法的CN4成本效益：英国国家卫生服务局（NHS）的观点

Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective

著录项

相似文献

相关主题

期刊订阅